This page has only limited features, please log in for full access.
Arsenic methylation capacity is associated with metabolic syndrome and its components among highly exposed populations. However, this association has not been investigated in low to moderately exposed populations. Therefore, we investigated arsenic methylation capacity in relation to the clinical diagnosis of metabolic syndrome in a low arsenic exposure population. Additionally, we compared arsenic methylation patterns present in our sample to those of more highly exposed populations. Using logistic regression models adjusted for relevant biological and lifestyle covariates, we report no association between increased arsenic methylation and metabolic syndrome in a population in which arsenic is regulated at 10 ppb in drinking water. However, we cannot rule out the possibility of a positive association between arsenic methylation and metabolic syndrome in a subsample of women with normal body mass index (BMI). To our knowledge this is the first investigation of arsenic methylation capacity with respect to metabolic syndrome in a low exposure population. We also report that methylation patterns in our sample are similar to those found in highly exposed populations. Additionally, we report that gender and BMI significantly modify the effect of arsenic methylation on metabolic syndrome. Future studies should evaluate the effectiveness of arsenic policy enforcement on subclinical biomarkers of cardiovascular disease.
Clare Pace; Julie Smith-Gagen; Jeff Angermann. Arsenic Methylation Capacity and Metabolic Syndrome in the 2013–2014 U.S. National Health and Nutrition Examination Survey (NHANES). International Journal of Environmental Research and Public Health 2018, 15, 168 .
AMA StyleClare Pace, Julie Smith-Gagen, Jeff Angermann. Arsenic Methylation Capacity and Metabolic Syndrome in the 2013–2014 U.S. National Health and Nutrition Examination Survey (NHANES). International Journal of Environmental Research and Public Health. 2018; 15 (1):168.
Chicago/Turabian StyleClare Pace; Julie Smith-Gagen; Jeff Angermann. 2018. "Arsenic Methylation Capacity and Metabolic Syndrome in the 2013–2014 U.S. National Health and Nutrition Examination Survey (NHANES)." International Journal of Environmental Research and Public Health 15, no. 1: 168.
Arsenic is a potent cardiovascular toxicant associated with numerous biomarkers of cardiovascular diseases in exposed human populations. Arsenic is also a carcinogen, yet arsenic trioxide is used as a therapeutic agent in the treatment of acute promyelotic leukemia (APL). The therapeutic use of arsenic is limited due to its severe cardiovascular side effects. Many of the toxic effects of arsenic are mediated by mitochondrial dysfunction and related to arsenic’s effect on oxidative stress. Therefore, we investigated the effectiveness of antioxidants against arsenic induced cardiovascular dysfunction. A growing body of evidence suggests that antioxidant phytonutrients may ameliorate the toxic effects of arsenic on mitochondria by scavenging free radicals. This review identifies 21 antioxidants that can effectively reverse mitochondrial dysfunction and oxidative stress in cardiovascular cells and tissues. In addition, we propose that antioxidants have the potential to improve the cardiovascular health of millions of people chronically exposed to elevated arsenic concentrations through contaminated water supplies or used to treat certain types of leukemias. Importantly, we identify conceptual gaps in research and development of new mito-protective antioxidants and suggest avenues for future research to improve bioavailability of antioxidants and distribution to target tissues in order reduce arsenic-induced cardiovascular toxicity in a real-world context.
Clare Pace; Ruben Dagda; Jeff Angermann. Antioxidants Protect against Arsenic Induced Mitochondrial Cardio-Toxicity. Toxics 2017, 5, 38 .
AMA StyleClare Pace, Ruben Dagda, Jeff Angermann. Antioxidants Protect against Arsenic Induced Mitochondrial Cardio-Toxicity. Toxics. 2017; 5 (4):38.
Chicago/Turabian StyleClare Pace; Ruben Dagda; Jeff Angermann. 2017. "Antioxidants Protect against Arsenic Induced Mitochondrial Cardio-Toxicity." Toxics 5, no. 4: 38.
Clare Pace; Tania Das Banerjee; Barrett Welch; Roxana Khalili; Ruben Dagda; Jeff Angermann. Monomethylarsonous Acid, But Not Inorganic Arsenic, Is a Mitochondrial-Specific Intoxicant in Vascular Smooth Muscle Cells. Free Radical Biology and Medicine 2014, 76, S109 .
AMA StyleClare Pace, Tania Das Banerjee, Barrett Welch, Roxana Khalili, Ruben Dagda, Jeff Angermann. Monomethylarsonous Acid, But Not Inorganic Arsenic, Is a Mitochondrial-Specific Intoxicant in Vascular Smooth Muscle Cells. Free Radical Biology and Medicine. 2014; 76 ():S109.
Chicago/Turabian StyleClare Pace; Tania Das Banerjee; Barrett Welch; Roxana Khalili; Ruben Dagda; Jeff Angermann. 2014. "Monomethylarsonous Acid, But Not Inorganic Arsenic, Is a Mitochondrial-Specific Intoxicant in Vascular Smooth Muscle Cells." Free Radical Biology and Medicine 76, no. : S109.